The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial
Open accessAbstract
BACKGROUND: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. OBJECTIVE: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability. DESIGN: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. (ClinicalTrials.gov: NCT00811954). SETTING: 57 sites in the United States and Puerto Rico. PATIENTS: Treatment-naive persons aged 18 years or older with HIV-1 RNA levels greater than 1000 copies/mL without resistance to nucleoside reverse transcriptase inhibitors or protease inhibitors. INTERVENTION: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d. MEASUREMENTS: Virologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 weeks and before 24 weeks or greater than 200 copies/mL at or after 24 weeks, and tolerability failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity. A secondary end point was a combination of virologic efficacy and tolerability. RESULTS: Among 1809 participants, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence within a margin of equivalence defined as -10% to 10%. Raltegravir and ritonavir-boosted darunavir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence of tolerability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily because of hyperbilirubinemia. For combined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both protease inhibitors. Antiretroviral resistance at the time of virologic failure was rare but more frequent with raltegravir. LIMITATION: The trial was open-label, and ritonavir was not provided. CONCLUSION: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Périard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.7.700 · Cited by 605
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60918-0 · Cited by 347
GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200202000-00035 · Cited by 270
Hazard Rate Models with Covariates
Prentice, R. L., & Kalbfleisch, J. D. (1979) · Biometrics · doi:10.2307/2529934 · Cited by 168
D’Ascenzo, F., Cerrato, E., Biondi‐Zoccai, G., Moretti, C., Omedè, P. L., Sciuto, F., Bollati, M., Modena, M. G., Gaïta, F., & Sheiban, I. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr456 · Cited by 96
Aberg, J. A., Tebas, P., Overton, E. T., Gupta, S. K., Sax, P. E., LANDAY, A. L., Falcon, R., Ryan, R. J., & Rosa, G. D. L. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0327 · Cited by 95
Sex-Based Outcomes of Darunavir–Ritonavir Therapy: A Single-Group Trial
Currier, J. S., Averitt, D., Hagins, D. P., Zorrilla, C., Feinberg, J., Ryan, R., Falcon, R., Tennenberg, A., Mrus, J. M., & Squires, K. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-6-201009210-00002 · Cited by 91
Self-citationStein, J. H., Brown, T. T., Ribaudo, H. J., Chen, Y., Yan, M., Lauer-Brodell, E., McComsey, G. A., Dubé, M. P., Murphy, R. L., Hodis, H. N., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835ce27e · Cited by 49
Self-citationDesign and Analysis of Three Treatment Equivalence Trials
Wiens, B. L., & Iglewicz, B. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00052-5 · Cited by 23
Cited by
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Sax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 396
Ofotokun, I., Titanji, K., Lahiri, C. D., Vunnava, A., Foster, A., Sanford, S. E., Sheth, A. N., Lennox, J. L., Knezevic, A., Ward, L., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw331 · Cited by 50
Self-citation
Metadata
- Authors
- Lennox, J. L., Landovitz, R. J., Ribaudo, H. J., Ofotokun, I., Na, L. H., Godfrey, C., Kuritzkes, D. R., Sagar, M., Brown, T. T., Cohn, S. E., McComsey, G. A., Aweeka, F., Fichtenbaum, C. J., Presti, R. M., Koletar, S. L., Haas, D. W., Patterson, K. B., Benson, C. A., Baugh, B. P., Leavitt, R. Y., Rooney, J. F., Seekins, D., Currier, J. S., & for the ACTG A5257 Team*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-10-07
- Volume
- 161
- Issue
- 7
- Pages
- 461-471
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2108676219
- Cited by
- 262
- References
- 10
- FWCI
- 26.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial. https://app.cochat.ai/papers/10.7326/m14-1084
- The paper
- Lennox, J. L., Landovitz, R. J., Ribaudo, H. J., Ofotokun, I., Na, L. H., Godfrey, C., Kuritzkes, D. R., Sagar, M., Brown, T. T., Cohn, S. E., McComsey, G. A., Aweeka, F., Fichtenbaum, C. J., Presti, R. M., Koletar, S. L., Haas, D. W., Patterson, K. B., Benson, C. A., Baugh, B. P., . . . for the ACTG A5257 Team*. (2014). Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial. Annals of Internal Medicine. https://doi.org/10.7326/m14-1084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.